OncoC4 takes its Siglec-10 bet into the clinic
The anti-Siglec-10 MAb ONC-841 features among the latest crop of first-in-human trial initiations.
Phase 1 entrants seek improved safety
First-in-human clinical trial initiations include yet another KRAS G12C inhibitor, and an ADC against PD-L1.
